Zoetis Q4 revenue rises 3%, beats analyst expectations

Zoetis

12/02/2026 12:07

Overview

Animal health firm's Q4 revenue rose 3%, beating analyst expectations

Adjusted EPS for Q4 beat analyst expectations

Company advanced OA pain franchise with new product approvals in Canada and EU

Outlook

Zoetis provides full-year 2026 revenue guidance of $9.825 bln to $10.025 bln

Company expects 3% to 5% organic operational growth in revenue for 2026

Zoetis forecasts adjusted diluted EPS of $7.00 to $7.10 for full year 2026

Result Drivers

U.S. SEGMENT - Revenue decreased 2% due to lower sales of monoclonal antibody products, offset by growth in parasiticides

INTERNATIONAL SEGMENT - Revenue increased 8%, driven by parasiticides and dermatology products

FISCAL YEAR ALIGNMENT - Operational changes contributed to revenue growth in the International segment

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$2.39 bln
$2.36 bln (13 Analysts)
Q4 Adjusted EPS
Beat
$1.48
$1.40 (15 Analysts)
Q4 EPS
$1.37


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Zoetis Inc is $156.44, about 21.6% above its February 11 closing price of $128.67

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release: ID:nBwcc1YSna

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)